Core Viewpoint - Tianyi Medical's stock closed at 34.02 yuan, down 2.52%, with a latest price-to-book ratio of 1.69 and a total market capitalization of 2.005 billion yuan [1] Company Overview - Ningbo Tianyi Medical Devices Co., Ltd. specializes in the research, development, production, and sales of medical polymer consumables in the fields of blood purification and ward care [1] - The company's main products include extracorporeal circulation blood lines for blood purification devices, single-use venous and arterial puncture devices, blood dialysis concentrates/dry powders, single-use integrated oxygen delivery tubes, feeding devices, and infusion tubes [1] - The company has received multiple honors, including being recognized as a provincial high-tech enterprise R&D center, a key high-tech enterprise under the National Torch Program, a Zhejiang Province innovative demonstration SME, and a "hidden champion" enterprise in Zhejiang Province [1] - Key products such as extracorporeal circulation blood lines, single-use venous and arterial puncture devices, and single-use integrated oxygen delivery tubes have been awarded as "Excellent Industrial Products of Zhejiang Province" [1] Financial Performance - In the latest financial report for 2024, the company achieved an operating income of 419 million yuan, a year-on-year increase of 9.98% [1] - The net profit was reported at -743,965.6 yuan, reflecting a year-on-year decrease of 101.17% [1] - The sales gross margin stood at 35.88% [1] Industry Comparison - Tianyi Medical's price-to-earnings (P/E) ratio (TTM) is -2695.54, significantly lower than the industry average of 46.75 [2] - The industry median P/E ratio is 29.99, indicating that Tianyi Medical is underperforming compared to its peers [2] - The company's price-to-book ratio of 1.69 is also lower than the industry average of 4.61 [2]
天益医疗收盘下跌2.52%，最新市净率1.69，总市值20.05亿元